Hyman Charles D boosted its stake in Pfizer Inc. (NYSE:PFE) by 6.7% during the second quarter, according to its most recent disclosure with the Securities and Exchange Commission. The institutional investor owned 130,724 shares of the biopharmaceutical company’s stock after buying an additional 8,233 shares during the period. Hyman Charles D’s holdings in Pfizer were worth $4,603,000 as of its most recent filing with the SEC.
A number of other hedge funds and other institutional investors have also recently modified their holdings of the company. Stelac Advisory Services LLC bought a new stake in shares of Pfizer during the second quarter valued at approximately $110,000. Catamount Wealth Management boosted its stake in shares of Pfizer by 14.2% in the first quarter. Catamount Wealth Management now owns 4,395 shares of the biopharmaceutical company’s stock valued at $130,000 after buying an additional 545 shares during the last quarter. Commonwealth Financial Services LLC boosted its stake in shares of Pfizer by 5.5% in the second quarter. Commonwealth Financial Services LLC now owns 4,023 shares of the biopharmaceutical company’s stock valued at $142,000 after buying an additional 210 shares during the last quarter. Stuart Chaussee & Associates Inc. boosted its stake in shares of Pfizer by 64.3% in the second quarter. Stuart Chaussee & Associates Inc. now owns 5,430 shares of the biopharmaceutical company’s stock valued at $193,000 after buying an additional 2,125 shares during the last quarter. Finally, Financial Management Professionals Inc. boosted its stake in shares of Pfizer by 21.9% in the second quarter. Financial Management Professionals Inc. now owns 5,517 shares of the biopharmaceutical company’s stock valued at $193,000 after buying an additional 993 shares during the last quarter. 69.65% of the stock is owned by institutional investors.
Pfizer Inc. (NYSE:PFE) traded down 0.27% on Friday, hitting $33.56. 14,819,706 shares of the company’s stock were exchanged. The company has a market cap of $203.56 billion, a PE ratio of 29.75 and a beta of 0.86. The company’s 50-day moving average price is $34.29 and its 200-day moving average price is $34.19. Pfizer Inc. has a 12-month low of $28.25 and a 12-month high of $37.39.
Pfizer (NYSE:PFE) last released its quarterly earnings results on Tuesday, August 2nd. The biopharmaceutical company reported $0.64 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.62 by $0.02. The business had revenue of $13.10 billion for the quarter, compared to the consensus estimate of $13.01 billion. Pfizer had a net margin of 14.88% and a return on equity of 23.37%. The business’s revenue was up 10.9% on a year-over-year basis. During the same period in the previous year, the firm earned $0.56 EPS. Analysts forecast that Pfizer Inc. will post $2.46 earnings per share for the current year.
The business also recently declared a quarterly dividend, which will be paid on Thursday, December 1st. Stockholders of record on Friday, November 11th will be paid a $0.30 dividend. This represents a $1.20 dividend on an annualized basis and a dividend yield of 3.58%. The ex-dividend date of this dividend is Tuesday, November 8th. Pfizer’s dividend payout ratio (DPR) is 95.24%.
Several brokerages have recently issued reports on PFE. Vetr upgraded shares of Pfizer from a “hold” rating to a “buy” rating and set a $38.08 target price on the stock in a research report on Tuesday, August 2nd. Sanford C. Bernstein restated an “outperform” rating on shares of Pfizer in a research report on Monday, September 26th. Piper Jaffray Cos. restated an “overweight” rating and set a $54.00 target price on shares of Pfizer in a research report on Monday, June 27th. BMO Capital Markets restated a “buy” rating and set a $40.00 target price on shares of Pfizer in a research report on Thursday, July 21st. Finally, JPMorgan Chase & Co. set a $40.00 target price on shares of Pfizer and gave the company a “buy” rating in a research report on Monday, July 25th. Ten analysts have rated the stock with a hold rating, fifteen have issued a buy rating and one has issued a strong buy rating to the company’s stock. Pfizer presently has a consensus rating of “Buy” and a consensus target price of $38.78.
Pfizer Company Profile
Pfizer Inc is a research-based global biopharmaceutical company. The Company is engaged in discovering, developing and manufacturing of healthcare products. Its portfolio includes medicines, vaccines and medical devices, as well as consumer healthcare products. Its products include Prevnar/Prevenar 13, Lyrica, Enbrel, Lipitor, Viagra, Sutent, BeneFIX, Genotropin, ReFacto, Xyntha and Enbrel.
Want to see what other hedge funds are holding PFE? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Pfizer Inc. (NYSE:PFE).
Receive News & Ratings for Pfizer Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Pfizer Inc. and related companies with MarketBeat.com's FREE daily email newsletter.